Sector News

Valeant said to step up talks on potential $800M deal for Egypt’s Amoun

June 18, 2015
Life sciences
Last month, reports said Valeant was eyeing up one of Egypt’s largest drugmakers. Now, word has it, those talks have progressed, and the Canadian pharma could be ready to pull the trigger in the coming weeks.
 
The serial buyer is in advanced negotiations to buy Amoun Pharmaceutical, Bloomberg reports, though no final decision has been made–meaning any deal could still fall apart. A sale could value the company between $700 million and $800 million, the news service’s sources said in May.
 
If Valeant were to grab Amoun, it would mark its third buyout of the year. After losing out on a months-long hostile takeover try for Allergan last November, the avid dealmaker has already snapped up North Carolina’s Salix–beating out rival bidder Endo–and the assets from bankrupt Seattle biotech Dendreon in the first half of 2015.
 
But unlike those transactions–which helped the company bulk up in GI and oncology, respectively–an Amoun tie-up would strengthen Valeant in fast-growing emerging markets. Beefing up in developing nations was one perk of the proposed Allergan merger, and a goal Pearson has already worked toward with deals like 2012’s for Mexican branded-generics company Atlantis Pharma.
 
It’s all part of Valeant’s strategy to expand through M&A in high-growth spaces–both geographic and therapeutic. Before the Salix and Dendreon deals, Valeant’s moves–like the Allergan play, and its 2013 pickup of Bausch + Lomb–were centered on skincare and eye care, two other hot fields Pearson had tabbed for expansion.
 
By Carly Helfand
 

comments closed

Related News

April 26, 2024

Former Bristol Myers CEO tapped as Novartis’ next board chair

Life sciences

Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.

April 26, 2024

GE HealthCare launches voice-activated, AI-powered ultrasound machines for women’s health

Life sciences

GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.

April 26, 2024

Scientists reveal new method that could reduce waste from drug manufacturing

Life sciences

Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.

How can we help you?

We're easy to reach